IDO
- Inhibitory Selectivity
- Solubility
| Catalog No. | Product Name | Solubility(25°C) | ||
|---|---|---|---|---|
| Water | DMSO | Alcohol | ||
| S7111 | NLG919 | <1 mg/mL | 15 mg/mL | 30 mg/mL |
| S7756 | Indoximod (NLG-8189） | <1 mg/mL | 1 mg/mL | <1 mg/mL |
| S7910 | Epacadostat (INCB024360) | <1 mg/mL | 87 mg/mL | 53 mg/mL |
| S7587 | INCB024360 analogue | <1 mg/mL | 54 mg/mL | 54 mg/mL |
| S8629 | BMS-986205 | <1 mg/mL | 82 mg/mL | 82 mg/mL |
| S8657 | PF-06840003 | <1 mg/mL | 46 mg/mL | 6 mg/mL |
IDO Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S7111 |
NLG919NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM in cell-free assays. Phase 1. |
Inhibitor sensitivity of tryptophan 2,3-dioxygenase (TDO) in N-formylkynurenine (NFK) Green assay. Dose-response curves of INCB024360, S7111, and NTRC 0820-0 with IC50 values 67 nM and 75 nM, respectively. |
|
| S7756 |
Indoximod (NLG-8189）Indoximod (NLG-8189), a methylated tryptophan, acts as an IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, and reverses IDO-mediated immune suppression. Phase 2. |
||
| S7910 |
Epacadostat (INCB024360)Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with IC50 of 10 nM and displays high selectivity over other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). |
Macrophages were treated with 2 μM obatoclax, 0.1 μM SNS-032, 3 μM SaliPhe, 0.1 μM JNJ872, 1 μM gemcitabine, 1 μM epacadostat or 1 μM NLG919 or remained non-treated and infected with mock or IAV (moi 3). After 24 h cell viability was measured by CTG and results were plotted. Mean ± SD, n=3.
|
|
| S8557 |
IDO inhibitor 1IDO inhibitor 1 is a potent inhibitor of IDO (indoleamine-(2,3)-dioxygenase) with IC50 of 3 nM. |
||
| S7587 |
INCB024360 analogueINCB024360 analogue is a potent, competitive IDO1 (indoleamine-(2,3)-dioxygenase) inhibitor with IC50 of 67 nM. Phase 2. |
||
| S8629New |
BMS-986205BMS-986205 is an irreversible inhibitor of IDO1 with an IC50 of 1.7 nM. It inhibits kynurenine production with IC50 values of 1.7, 1.1 and > 2000 in human HeLa, HEK293 expressing human IDO-1 and tryptophan-2, 3-dioxygenase cell-based assays. |
||
| S8657 |
PF-06840003PF-06840003 is a highly selective orally bioavailable IDO-1 inhibitor. Although it has moderate hIDO1 enzyme inhibition (IC50 0.41 μM), it is a highly efficient compound (LE 0.53, LipE 5.1), driven by its tight packing within the enzyme, as well as the high density of hydrogen bonds it forms with hIDO-1 despite its small size. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S7111 |
NLG919NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM in cell-free assays. Phase 1. |
Inhibitor sensitivity of tryptophan 2,3-dioxygenase (TDO) in N-formylkynurenine (NFK) Green assay. Dose-response curves of INCB024360, S7111, and NTRC 0820-0 with IC50 values 67 nM and 75 nM, respectively. |
|
| S7756 |
Indoximod (NLG-8189）Indoximod (NLG-8189), a methylated tryptophan, acts as an IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, and reverses IDO-mediated immune suppression. Phase 2. |
||
| S7910 |
Epacadostat (INCB024360)Epacadostat (INCB024360) is a potent and selective indoleamine 2,3-dioxygenase (IDO1) inhibitor with IC50 of 10 nM and displays high selectivity over other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). |
Macrophages were treated with 2 μM obatoclax, 0.1 μM SNS-032, 3 μM SaliPhe, 0.1 μM JNJ872, 1 μM gemcitabine, 1 μM epacadostat or 1 μM NLG919 or remained non-treated and infected with mock or IAV (moi 3). After 24 h cell viability was measured by CTG and results were plotted. Mean ± SD, n=3.
|
|
| S8557 |
IDO inhibitor 1IDO inhibitor 1 is a potent inhibitor of IDO (indoleamine-(2,3)-dioxygenase) with IC50 of 3 nM. |
||
| S7587 |
INCB024360 analogueINCB024360 analogue is a potent, competitive IDO1 (indoleamine-(2,3)-dioxygenase) inhibitor with IC50 of 67 nM. Phase 2. |
||
| S8629New |
BMS-986205BMS-986205 is an irreversible inhibitor of IDO1 with an IC50 of 1.7 nM. It inhibits kynurenine production with IC50 values of 1.7, 1.1 and > 2000 in human HeLa, HEK293 expressing human IDO-1 and tryptophan-2, 3-dioxygenase cell-based assays. |
||
| S8657 |
PF-06840003PF-06840003 is a highly selective orally bioavailable IDO-1 inhibitor. Although it has moderate hIDO1 enzyme inhibition (IC50 0.41 μM), it is a highly efficient compound (LE 0.53, LipE 5.1), driven by its tight packing within the enzyme, as well as the high density of hydrogen bonds it forms with hIDO-1 despite its small size. |
